A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE PHARMACOKINETICS OF PF-06700841 FOLLOWING SINGLE ORAL ADMINISTRATION OF MODIFIED RELEASE TABLETS COMPARED TO IMMEDIATE RELEASE TABLETS UNDER FASTED CONDITIONS
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2019
At a glance
- Drugs PF 6700841 (Primary)
- Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Jan 2019 Planned End Date changed from 12 Mar 2019 to 14 Feb 2019.
- 24 Jan 2019 Planned primary completion date changed from 12 Mar 2019 to 14 Feb 2019.
- 24 Jan 2019 Status changed from not yet recruiting to recruiting.